RECEIVED CENTRAL FAX CENTER

JUN 1 3 2005

MARSHALL, GERSTEIN & BORUN LLP
ATTORNEYS AT LAW
6300 SEARS TOWER
233 SOUTH WACKER DRIVE
CHICAGO, ILLINOIS 60606-6357
(312) 474-6300
FAX: (312) 474-0448

June 13, 2005

FACSIMILE TRANSMISSION SHEET

COMPANY

United States Patent & Trademark Office

FAX NO.

(703) 872-9306

FROM: Michael Muczynski

EXTENSION:

805

PAGES (INCLUDING THIS PAGE):

CLIENT NO:

28341

MATTER NO:

6127NDIVIUS

PLEASE CONFIRM RECEIPT:

Nο

COUNTRY CODE:

211

MESSAGE:

Scrial No.: 10/705,660 Confirmation: 6143 Applicants: Bowersock et al. Filed: November 10, 2003

Title: METHOD OF VACCINATING VERTEBRATES

Art Unit: 1644

Examiner: Not yet assigned

Atty Docket: 28341/6127NDIV1US

Customer No.: 04743

Enclosed is a copy of a Supplemental Information Disclosure Statement (1 page), Form PTO-1449

(1 page), and other documents (9 pages).

Please contact Jen at (312) 474-6805 if you do not receive all of the pages in good condition.

This transmission contains confidential information intended only for the addressee. If you are not the addressee, any disclosure or use of this information by you is strictly prohibited. If you have received this facsimile in error, please notify us by telephone immediately.

Page 2 RECEIVED

CENTRAL FAX CENTER

JUN 1 3 2005

(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Serial No.	: 10/705,660) Date of Deposit:
Confirmation	: 6143) June 13, 2005
A . 1	. Damma ala at al)
Applicants	: Bowersock et al.) I hereby certify that this paper and all
Filed	: November 10, 2003	 documents referred to herein as being enclosed are being transmitted to the
Title: METH	OD OF VACCINATING) United States Patent and Trademark
VERTEBRA1	res) Office, via facsimile to:
) Mail Stop Amendment
Art Unit	: 1644) facsimile number (703) 872-9306.
Examiner	: Not yet assigned)
A 44 - 70 - 1-4	20241//12771777171717	? 1/0 11
	: 28341/6127NDIV1US	
Customer No.	: 04743	? When Mucrelle,
) Michael Muczynskii

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

The documents listed on the enclosed Form PTO-1449 are identified pursuant to 37 CFR §§ 1.56, 1.97, and 1.98. Copies of the documents are enclosed as necessary.

Entry and consideration of the disclosed documents are solicited.

Respectfully submitted,

MARSHALL, GERSTEIN & BORUN LLP

D.

June 13, 2005

Michael Muczynski

Reg. No. 48,642

Attorney for Applicants

6300 Scars Tower 233 South Wacker Drive Chicago, IL 60606 (312) 474-6300

Sheet 1 of 1

Form PTO-1449 (Modified)	U.S. Department of Commerce	Atty. Docket No.	Scrial No.	
	Patent and Trademark Office	28341/6127NDIV1	10/705,660	
		Applicant		
INFORMATION DISC	LOSURE STATEMENT	Bowersock et al.		
INFORMATION DISC	LOSURE STATEMENT	Bowersock et al.		
INFORMATION DISC	LOSURE STATEMENT	Bowersock et al. Filing Date	Art Unit	

U.S. PATENT DOCUMENTS							
*Examiner Initials		Document Number	Issue Date	Name	Class	Subclass	Filing Date if Appropriate

FOREIGN PATENT DOCUMENTS							
*Examiner Initials	Document Number	Publication Date	Country	Class	Subclass	Translation	
						Yes	No

O	THER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)
·	Jackson, R. et al., "Preparation of 2-5 µm alginate microparticles by emulsification for orul vaccine delivery: Effects of surfactant type, crosslinker, and mixer speed on particle size," Pharmaceutical Research (New York), Vol. 14, No. 11 Suppl., November 1997, pp. S47-S48, XP008000504, Annual Meeting of the American Association of Pharmaceutical Scientists; Boston, Massachusetts, USA; November 2-6, 1997, ISSN: 0724-8741.
	European Search Report from the European Patent Office, in counterpart application no. 05005506.0, mail date April 22, 2005.
	European Search Report from the European Patent Office, in counterpart application no. 05005507.8, mail date April 22, 2005.

CONTRACTOR				
EXAMINER	DATE CONSIDERED			
	i			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.